Marshall Edwards' CEO to Present at Needham Healthcare Conference
03 juin 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...
Marshall Edwards Announces Final Results From Halted Phase 3 Clinical Trial of Phenoxodiol
01 juin 2010 08h31 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 1, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Report on Phase II Clinical Study of Marshall Edwards' Phenoxodiol in Prostate Cancer to Be Presented at ASCO
21 mai 2010 09h00 HE
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - May 21, 2010) - Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled "A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer...
Marshall Edwards, Inc. Announces Grants Under Nasdaq Rule 5635
29 avr. 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 29, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards Appoints New President and CEO
26 avr. 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards, Inc. Receives Notice of Compliance With Nasdaq Continued Listing Requirements
20 avr. 2010 09h00 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - April 20, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, today...
Marshall Edwards, Inc. Announces Stockholder Approval and Implementation of 1:10 Reverse Stock Split
31 mars 2010 08h00 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
08 févr. 2010 08h00 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA--(Marketwire - February 8, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL)
announced that Christopher Naughton had resigned as a member of the Board
of Directors effective February 5,...
Analysis of Marshall Edwards, Inc.'s OVATURE Trial to Proceed Following Database Lock
21 janv. 2010 18h34 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - January 21, 2010) - The Board of Directors of Marshall Edwards,
Inc. today advised that analysis of tumor response data from the OVATURE
trial will be performed in the...
Marshall Edwards, Inc. Appoints Acting CEO
01 déc. 2009 00h01 HE
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 1, 2009) - Novogen Limited
advises that CEO and Managing Director Christopher Naughton will cease his
employment with the Company from...